An open trial regarding the safety and efficacy of blonanserin for patients with gambling disorder

An open trial regarding the safety and efficacy of blonanserin for patients with gambling disorder - Open trial of blonanserin for gambling disorder

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020669

Enrollment

Registered

2016-01-21

Start date

2016-01-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gambling disorder

Interventions

Blonanserin, 2-12 mg/day, 8 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Gambling disorder as defined by DSM-5 2. Outpatients of Chiba University Hospital 3. 20<= age at consent < 65 4. 5>= SOGS score

Exclusion criteria

Exclusion criteria: 1. Incompetent 2. Pregnant, nursing, or being expected as so 3. F2 or F0 by ICD-10 4. uncontrolled physical illness 5. taking antipsychotic drugs within 28 days before 6. taking prohibited with blonanserin 7. history of allergic reaction for blonanserin 8. history of malignant syndrome or tardive dyskinesia caused by antipsychotic drugs 9. participated other clinical trials within 3 month before 10. 15 >= MADRS 11. 15 >= YMRS 12. 3 >= overall severity of DIEPSS 13. history of suicide attempt within one years before 14. contraindicated by the doctor in charge

Design outcomes

Primary

Measure	Time frame
Overall severity of DIEPSS at 8 weeks	—

Secondary

Measure	Time frame
The change of the scores in GSAS, PG-YBOCS, BIS-11, and CGI-C at 8 weeks	—

Countries

Japan

Contacts

Public ContactAkihiro Shiina

Chiba University Department of psychiatry, Graduate school of medicine

shiina-akihiro@faculty.chiba-u.jp+81-42-222-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026